Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

Blood (2024) 144 (16): 1722–1731.

https://doi.org/10.1182/blood.2024023840

Published: 2024

Includes: Supplemental data

Journal Articles

TP53 G ene a llelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion

Blood (2023) 142 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2023-179171

Published: 2023

Journal Articles

Multiomic Characterization of Myelodysplastic Neoplasms (MDS) with Micromegakaryocytes Highlights the Role of EZH2-RUNX1 deregulation in Disease Physiopathology and Response to Targeted Therapies

Blood (2023) 142 (Supplement 1): 4116.

https://doi.org/10.1182/blood-2023-188848

Published: 2023

Journal Articles

Results of Treatment Approaches in Myeloid Neoplasms According to TP53 Allelic Status (Multi-hit vs Monoallelic), a Real World Analysis

Maria Sola, Francisco Beas, Laura Palomo, Mar Tormo, Ana Riera, Nicolas Díaz Varela, Teresa Bernal, Sara García, Concepción Fernández, Nieves Garcia-Gisbert, Félix López Cadenas, Barbara Tazon, Adoracion Blanco, Sara Garrido Paniagua, Ana Pérez González, Andres Jerez, Julia Montoro, Olga Salamero, David Valcarcel

Blood (2023) 142 (Supplement 1): 3227.

https://doi.org/10.1182/blood-2023-187101

Published: 2023

Journal Articles

Clinical Impact of the New Bone Marrow Blasts Cutoff Defined By the International Classification Consortium (ICC) in Myeloid Neoplasms with Mutated TP53 gene

Blood (2023) 142 (Supplement 1): 3235.

https://doi.org/10.1182/blood-2023-181698

Published: 2023

Journal Articles

Prevalence, Dynamics and Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Newly Diagnosed Cancer Patients

Blood (2023) 142 (Supplement 1): 5593.

https://doi.org/10.1182/blood-2023-189503

Published: 2023

Journal Articles

Clinical and Molecular Characterization of Patients with Therapy Related Myeloid Neoplasms (TRMN)

Blood (2023) 142 (Supplement 1): 3224.

https://doi.org/10.1182/blood-2023-188701

Published: 2023

Journal Articles

Germline Predisposition in Myeloid Neoplasms Aged ≥50: A Novel Approach for Allogeneic Stem Cell -Transplantation Decision-Making

Blood (2023) 142 (Supplement 1): 5663.

https://doi.org/10.1182/blood-2023-179234

Published: 2023

Journal Articles

Clonal Hematopoiesis of Indeterminate Potential (CHIP) Related to the Etiology of Ischemic Stroke

Clàudia Pellín Jou, Jose Manuel Campos Zarraquiños, Laura Palomo, Carlos Lázaro Hernández, Marta Aurora Rubiera del Fueyo, Sara Garrido Paniagua, Sofia Laura Muzio, Maria Laura Fox, Pamela Acha, Prudencio Lozano Iragüen, David Valcarcel, Maria Julia Montoro, Francesc Bosch

Blood (2023) 142 (Supplement 1): 5601.

https://doi.org/10.1182/blood-2023-180508

Published: 2023

Journal Articles

Early-Onset Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) without SF3B1 Mutations in Adults: Enrichment with Germline Variants in Genes Responsible for Congenital Sideroblastic Anemias

Sandra Novoa Jáuregui, Tzu Chen, Sara Torres-Esquius, Salvador Carrillo-Tornel, Marta Santiago, Teresa Bernal Del Castillo, Francisca Maria Hernandez, Alessandro Liquori, Ivan Martin Castillo, Mar Tormo, Barbara Tazon, Adoracion Blanco, Laura Palomo, Jose Cervera, Francesc Bosch, David Valcarcel, Maria Diez-Campelo, Julia Montoro, Andres Jerez

Blood (2023) 142 (Supplement 1): 4610.

https://doi.org/10.1182/blood-2023-185836

Published: 2023

Journal Articles

The Transcriptional Impact of 5q Deletion in MDS at Single Cell Resolution

Blood (2023) 142 (Supplement 1): 1850.

https://doi.org/10.1182/blood-2023-186173

Published: 2023

Journal Articles

Bone Marrow Cytokines Concentrations in Myelodysplastic Neoplasms: Its Correlation with the Immune Populations and Clonal Hematopoiesis

Antonieta Molero Yordi, Soraya Peralta Garzón, Laura Gallur, Barbara Tazon, Daniel Medina, Victor Navarro Garces, Maria Julia Montoro, Silvia Saumell, Tamara Jimenez, Félix López Cadenas, Teresa Ezponda, Ana Alfonso Pierola, Felipe Prosper, Maria Diez-Campelo, Olga Salamero, Ana Pérez González, Sara Garrido Paniagua, David Valcarcel

Blood (2023) 142 (Supplement 1): 6457.

https://doi.org/10.1182/blood-2023-185616

Published: 2023

Journal Articles

Role and Prevalence of Risk Factors That Trigger Therapy Related Myeloid Neoplasms (TRMN) in Patients with Previous Treated Breast Cancer

Oriol Calvete, Rashmi Kanagal-Shamanna, Julia Mestre, Guillermo Montalban-Bravo, Courtney D. DiNardo, Koji Sasaki, Jessica Aranda, Pamela Acha, Blanca Xicoy, Ana Pérez González, Laura Palomo, Maria Julia Montoro, Mireia Margeli, Francesc Sole

Blood (2023) 142 (Supplement 1): 4593.

https://doi.org/10.1182/blood-2023-188887

Published: 2023

Journal Articles

Usefulness of Peripheral Blood Samples in Diagnosis and Prognosis Assessment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Low Risk Patients Using Next Generation Sequencing

Blood (2023) 142 (Supplement 1): 6477.

https://doi.org/10.1182/blood-2023-180680

Published: 2023

Journal Articles

Assessment of Artificial Intelligence Language Models and Information Retrieval Strategies for QA in Hematology

Maria R Cervera, David Bermejo-Peláez, Miguel Gómez-Álvarez, Marta Hidalgo Soto, Ana Mendoza-Martínez, Adriana Oñós Clausell, Oscar Darias, Jaime García-Villena, Celina Benavente Cuesta, Julia Montoro, Joaquin Martínez-López, Miguel Luengo-Oroz

Blood (2023) 142 (Supplement 1): 7175.

https://doi.org/10.1182/blood-2023-178528

Published: 2023

Journal Articles

Characterization of Terminal Erythroid Differentiation (TED) and Its Prognosis Impact Inpatients with Myelodysplastic Syndrome (MDS)

Marc Bosch Schips, Julia Montoro, Félix López Cadenas, Alba Mesa, Víctor Navarro Garcés, Ana Pérez, Laura Gallur, Silvia Saumell, Mayda Navarrete, Margarita Ortega, Bárbara Tazón, Antonieta Molero, Olga Salamero, Sandra Novoa Jáuregui, Sofia Laura Muzio, Francesc Bosch, David Valcárcel

Blood (2022) 140 (Supplement 1): 12308–12310.

https://doi.org/10.1182/blood-2022-157434

Published: 2022

Journal Articles

TP53 Allelic State in Myelodysplastic Syndromes with 5q Deletion

Maria Julia Montoro Gómez, Laura Palomo, Pablo Vidal, Francisco Fuster-Tormo, Esperanza Such, Margarita Ortega, Teresa González, Felix Lopez-Cadenas, Sara Garcia-Avila, Nieves Garcia-Gisbert, Elvira Mora Casterá, Eugenia Rivero, Francesc Bosch, Andrés Jerez, Maria Diez-Campelo, Francesc Solé, David Valcárcel

Blood (2022) 140 (Supplement 1): 6949–6951.

https://doi.org/10.1182/blood-2022-165257

Published: 2022

Journal Articles

Bone Marrow Microenvironment Changes in Myelodysplastic Neoplasms and Its Relationship with Clonal Hematopoiesis and Disease Progression

Antonieta Molero Yordi, Soraya Peralta, Laura Gallur, Bárbara Tazón, Víctor Navarro Garcés, Silvia Saumell, Maria Julia Montoro, Olga Salamero, Ana Pérez González, Sara Garrido, Maria Sola, Tamara Jimenez, Félix López Cadenas, Teresa Ezponda, Ana Alfonso-Pierola, Lídia Altimiras, Maria Diez-Campelo, Felipe Prosper, David Valcárcel

Blood (2022) 140 (Supplement 1): 4024–4025.

https://doi.org/10.1182/blood-2022-163188

Published: 2022

Journal Articles

Supervised Machine Learning Improves Risk Stratification in Newly Diagnosed Myelodysplastic Syndromes: An Analysis of the Spanish Group of Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 1132–1134.

https://doi.org/10.1182/blood-2022-159429

Published: 2022

Journal Articles

IPSS-M Applicability and Clinical Impact in Decision-Making Process in Real-Life Clinical Practice

Sandra Novoa Jáuregui, Laura Palomo, Ana Pérez, Bárbara Tazón, Maria Julia Montoro, Adoracion Blanco, Silvia Saumell, Laura Gallur, Eugenia Rivero, Sara Garrido, Marc Bosch Schips, Sofia Laura Muzio, Margarita Ortega, Antonieta Molero Yordi, Francesc Bosch, David Valcárcel

Blood (2022) 140 (Supplement 1): 6966–6967.

https://doi.org/10.1182/blood-2022-168705

Published: 2022

NARROW

Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

TP53 G ene a llelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion

Multiomic Characterization of Myelodysplastic Neoplasms (MDS) with Micromegakaryocytes Highlights the Role of EZH2-RUNX1 deregulation in Disease Physiopathology and Response to Targeted Therapies

Results of Treatment Approaches in Myeloid Neoplasms According to TP53 Allelic Status (Multi-hit vs Monoallelic), a Real World Analysis

Clinical Impact of the New Bone Marrow Blasts Cutoff Defined By the International Classification Consortium (ICC) in Myeloid Neoplasms with Mutated TP53 gene

Prevalence, Dynamics and Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Newly Diagnosed Cancer Patients

Clinical and Molecular Characterization of Patients with Therapy Related Myeloid Neoplasms (TRMN)

Germline Predisposition in Myeloid Neoplasms Aged ≥50: A Novel Approach for Allogeneic Stem Cell -Transplantation Decision-Making

Clonal Hematopoiesis of Indeterminate Potential (CHIP) Related to the Etiology of Ischemic Stroke

Early-Onset Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) without SF3B1 Mutations in Adults: Enrichment with Germline Variants in Genes Responsible for Congenital Sideroblastic Anemias

The Transcriptional Impact of 5q Deletion in MDS at Single Cell Resolution

Bone Marrow Cytokines Concentrations in Myelodysplastic Neoplasms: Its Correlation with the Immune Populations and Clonal Hematopoiesis

Role and Prevalence of Risk Factors That Trigger Therapy Related Myeloid Neoplasms (TRMN) in Patients with Previous Treated Breast Cancer

Usefulness of Peripheral Blood Samples in Diagnosis and Prognosis Assessment of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Low Risk Patients Using Next Generation Sequencing

Assessment of Artificial Intelligence Language Models and Information Retrieval Strategies for QA in Hematology

Characterization of Terminal Erythroid Differentiation (TED) and Its Prognosis Impact Inpatients with Myelodysplastic Syndrome (MDS)

TP53 Allelic State in Myelodysplastic Syndromes with 5q Deletion

Bone Marrow Microenvironment Changes in Myelodysplastic Neoplasms and Its Relationship with Clonal Hematopoiesis and Disease Progression

Supervised Machine Learning Improves Risk Stratification in Newly Diagnosed Myelodysplastic Syndromes: An Analysis of the Spanish Group of Myelodysplastic Syndromes

IPSS-M Applicability and Clinical Impact in Decision-Making Process in Real-Life Clinical Practice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only